Abdominal imaging in ICU patients with viral pneumonia: Are findings in COVID-19 patients really different from those observed with non-SARS-CoV-2 viral pneumonia?

Edouard Reizine, Sebastien Mule, Nicolas De Prost, Nicolas Mongardon, Jean-François Deux, Hicham Kobeiter, Alain Luciani

Purpose: To evaluate and compare the prevalence and type of abdominal involvements identified on CT scans in COVID-19 critically ill patients to those observed in critically ill patients with non-SARS-CoV-2 viral pneumonia.

Methods: Monocentric IRB approved retrospective study comparing all abdominal CT scans performed for patients admitted in the ICU with COVID-19 and those performed in a historical cohort of ICU patients with non-SARS-CoV-2 viral pneumonia. For each patient, gallbladder abnormality, acute pancreatitis signs, acute adrenal infarction, renal infarcts, bowel wall thickening and CT scan signs of bowel ischemia were assessed. Results were then compared between critically ill COVID-19 and non-COVID-19 patients (Chi-2 or Fisher exact tests for categorical data and Student t-test or Mann-Whitney U test for continuous data as appropriate).

Results: Ninety-nine COVID-19 patients and 45 non-COVID-19 patients were included. No difference was found between the rate of abnormal findings comparing COVID-19 patients and patients with other viral pneumonia (63/99 [64%] vs 27/45 [61%], p=0.94). Acute pancreatitis signs were more commonly seen in COVID-19 patients but without statistically difference between groups (14/99 [14%] vs 3/45 [6.7%], p=0.31). Bowel wall thickening was slightly more commonly seen in patients with other viral pneumonia (18/99 [18%] vs 11/45 [24%], p=0.52), however ischemic features were observed in higher rate in the COVID-19 group, although without reaching statistically significant differences (7/99 [7.1%] vs 2/45 [4.4%], p=0.75).

Conclusion: The rate and severity of abdominal involvement demonstrated by CT in ICU patients hospitalized for COVID-19 although high were not different to that observed in patients with other severe viral pneumonias.

Key points
Abdominal abnormal findings were found in 62% ICU patients with viral pneumonia.

The rate and type of abdominal involvement demonstrated by CT were similar in all types of severe viral pneumonias.
1. Background

Although Coronavirus disease 2019 (COVID-19) is mainly defined by its respiratory symptoms [1,2], it has been reported that the virus can also affect the digestive system [3]. Hence, a preliminary study reported significant findings in up to 57% of COVID-19 patients referred for abdominopelvic computed tomography (CT) [4], especially regarding digestive tract abnormalities [4]. In another study, up to one third of the patients who underwent a CT scan were reported to have bowel wall abnormalities and signs of bowel ischemia were seen in 20% of Intensive Care Unit (ICU) patients [2.7% of ICU patients] [5]. Although the precise mechanisms accounting for these developments remain poorly understood, thromboembolic episodes could occur more frequently in COVID-19 patients [6]. A recent study showed that non-occlusive mesenteric ischemia was the most common pattern suggestive of microvascular involvement [7]. In addition, other ischemic damages have been reported such as renal infarctions, which was commonly identified on abdominal CT [4] and similarly, a high incidence of acute adrenal infarction have been reported on initial chest CT in severe COVID-19 patients, which might be a sign of a poorer prognosis [8]. Besides vascular injuries, other abnormal abdominal findings have been reported such as a dilated sludge-filled gallbladder, notified in more than half of right upper quadrant ultrasound performed in patients with COVID-19 [9] or signs of acute pancreatitis [9]. To date, there is no evidence of prevalent CT scan signs of acute pancreatitis in patients with COVID-19, even if the pancreas is target organs of SARS-CoV-2 because ACE2 receptor is expressed in the pancreas acinar and islet cells [10].

Interestingly, abdominal imaging findings seem related to the intrinsic diseases severity as patients with moderate to severe COVID-19 pneumonia have a significantly higher rate of vascular complications in the abdomen and pelvis [9]. Nevertheless, those findings, notably bowel ischemia, are not uncommon in critically ill patients regardless of the etiology [11,12]. Interestingly, in a small autopsy series focusing on pulmonary embolism, alveolar capillary microthrombi were 9 fold more prevalent in patients with COVID-19 than in patients with influenza [13], suggesting that abdominal abnormalities, and especially those secondary to thromboembolism could occur more commonly in patients with COVID-19 than in patients with other viral pneumonia.

Our purpose was hence to evaluate and compare the prevalence and type of abdominal involvements identified on CT scans in COVID-19 critically ill patients to those observed in critically ill patients with non-SARS-CoV-2 viral pneumonia.

2. Materials and methods

This retrospective study was approved by the local institution review board and informed consent was waived.

2.1. Population

All patients hospitalized in ICU for or with a viral pneumonia between October 2009 and February 2021 were extracted from an institutional ICU database. Patients without RT-PCR to confirm the viral pneumonia or patients for whom the viral pneumonia was not the cause of ICU hospitalization were excluded. All patients who underwent an enhanced abdomen and pelvic CT were finally included. Demographic data including age, sex, main comorbidity such as Hypertension, Chronic kidney disease, Diabetes, Obesity (BMI >30kg/m²), Cancer, Solid organ transplantation or immune-suppressive medications and Cirrhosis, was collected for each patient according to the clinical chart of ICU hospitalization. Details of ICU hospitalization including acute respiratory failure, bacterial pulmonary coinfection and liver function tests at admission, numbers of days in ICU and deaths during the ICU hospitalization were noted.

The ICU hospitalization day on which the abdominal CT was performed and details of the CT protocols were reported. For patients who underwent several CT during the hospitalization, only one CT per patient was analyzed.

Two groups of patients were compared: the COVID-19 group for patients admitted in the ICU with COVID-19 confirmed by reverse transcription-polymerase chain reaction (RT-PCR), and the Non-COVID-19 group for ICU patients with non-SARS-CoV-2 viral pneumonia.

2.2. CT analysis

All patients underwent a 64-section contrast-enhanced CT scanner (Discovery HD 750; GE Healthcare for patients before 2016 and Revolution CT; GE Healthcare for patients after 2016). The number of patients undergoing unenhanced, arterial phase and portal-phase acquisitions performed were assessed. A volume of 2 mL/kg body weight of nonionic contrast material (iomeron® 350, Bracco Imaging, Milano, Italy or iobitridol, 350mg iodine /mL, Xenetix, Guerbet, Aulnay Franchise) was injected into an antecubital vein at a flow rate of 5 mL/sec followed by 50 mL of saline solution at the same flow rate. Acquisition parameters were as follows: tube voltage, 120 kVp; section collimation, 64 × 1,25 mm; helical pitch, 1,375; reconstructed image thickness 1,25mm.

All CT scans were reviewed by 2 radiologists specialized in abdominal imaging (with respective 5 and 15 years of experience) in consensus who were both blinded to the final diagnosis. For each patient the following features were assessed: presence of free air, free fluid or fluid collection, gallbladder abnormality defined as disease associated to wall edema, acute pancreatitis signs, acute adrenal hemorrhage, renal infarcts, spleen infarcts, bowel wall thickening, bowel distension and CT scan signs of bowel ischemia including lack of bowel wall enhancement, intramural pneumatisos, mesenteric or portal venous gas, and mesenteric arterial or venous thrombosis [14].

Relevant imaging findings were defined as abnormalities found on CT including exclusively acute pancreatitis signs, acute adrenal hemorrhage, renal infarcts, spleen infarcts, bowel wall thickening and CT scan signs of bowel ischemia.

For each patient, the lung involvement was quantitatively estimated using a 0 to 5 score as previously reported [15]: 0, no involvement; 1, <5% involvement; 2, 25% involvement; 3, 26–49% involvement; 4, 50–75% involvement; 5, >75% involvement [15].

2.3. Statistical analysis

For statistical analysis, categorical variables are presented as numbers and percentages, and continuous variables as means (standard deviations) or medians (ranges), depending on the distribution of values. A Kolmogorov-Smirnov test was used to assess the normality of distributions. Comparison of categorical variables was performed using Chi-2 or Fisher exact tests. Continuous data were compared using the Student t-test or Mann-Whitney U test, as appropriate. No matching was performed between the two populations. Finally, a logistic regression was used to identity statistically significant predictors of relevant imaging findings between the lung involvement, the COVID-19 infection, the clinical state of the patients in ICU and the outcome.

3. Results

3.1. Population

Four hundred and forty-four patients with COVID-19 confirmed by RT-PCR and 283 patients with non-SARS-CoV-2 viral pneumonia were eligible to this study. A total of 99 COVID-19 patients (99/411
In COVID-19 patients, the abdominal CT scans were performed after a longer delay in ICU than with other pneumonia (mean 11 days [2, 20] vs 6 days [1, 11] respectively, p=0.03) while more patients were intubated or under an extracorporeal membrane oxygenation (ECMO) (74/99 [75%] vs 26/45 [58%] p=0.06 and 16/99 [16%] vs 1/45 [2.2%] p=0.03 respectively).

The lung involvement was more severe for COVID-19 patients with a significantly higher prevalence of 50%−75% involvement and above 75% involvement (28/99 [28%] vs 3/45 [6.7%] respectively and 20/99 [20%] vs 2/45[2.2] respectively, p<0.01).

3.2. Abdominal imaging findings

The main clinical settings in which the CT were performed were sepsis (49/144, [34%]), shock (16/144, [11%]), bleeding (18/144, [13%]), abdominal pain (11/144, [9%]) and bowel ischemia for 9 patients (9/144, [6%]).

Results of abdominal imaging findings are provided in Table 3 while main abdominal imaging findings are summarized in Fig. 1.

Regarding the CT protocol, the rates of unenhanced (73/99 [74%] vs 39/45 [87%], p=0.13), arterial phase (52/99 [53%] vs 20/45 [44%], p=0.47) and portal phase acquisitions (89/99 [90%] vs 40/45 [89%], p=0.09) were similar in both groups.

Fifty-four patients did not show any abnormal findings on CT (54/144 [38%]). Of the 90 patients with abnormal CT (90/144 [62%]), the most common findings were gallbladder abnormalities in 31 patients (31/90 [34%]) and bowel wall thickening in 29 patients (29/90 [32%]). Signs of bowel ischemia were noted in 9 patients (9/10[10%]), including 1 patient with simultaneous splenic and renal infarcts and two patients with renal infarcts alone. Seventeen patients showed acute pancreatitis signs (17/90 [19%]), including 5 patients with simultaneous bowel wall thickening, and two patients with additional renal infarcts.

No difference was found between the rate of abnormal findings when comparing COVID-19 patients and patients with other viral pneumonia (63/99 [64%] vs 27/45 [61%], p=0.94) as well as the rate of relevant imaging findings (42/99 [42%] vs 18/45 [40%], p=0.93). The

### Table 1

Comparison of demographics data and biological data of ICU patients with COVID-19 or with other viral pneumonia.

|                          | Other viral pneumonia, N = 45 | COVID-19, N = 99 | p-value |
|--------------------------|-------------------------------|------------------|---------|
| Male                     | 23 (51%)                      | 79 (80%)         | <0.01   |
| Age (years), median (IQR)| 65 (54, 76)                   | 61 (54, 70)      |         |
| Hypertension             | 18 (40%)                      | 59 (60%)         | 0.22    |
| Chronic kidney disease   | 7 (16%)                       | 6 (16%)          | 0.05    |
| Diabetes                 | 12 (27%)                      | 44 (48%)         | 0.11    |
| Obesity (BMI>30kg/m2)    | 6 (13%)                       | 35 (35%)         | 0.07    |
| BMI, median (IQR)        | 23.0 (21.1, 29.4)             | 28.0 (25.0, 33.2)| 0.01    |
| Cancer                   | 12 (27%)                      | 5 (5.1%)         | <0.01   |
| Solid organ transplantation or immune-suppressive medications | 12 (27%) | 6 (6.1%) | <0.01 |
| Cirrhosis                | 7 (16%)                       | 2 (2.0%)         | <0.01   |
| Recent surgery           | 3 (6.7%)                      | 1 (1.0%)         | <0.01   |
| History of thromboembolic event | 7 (16%) | 5 (5.1%) | 0.05 |

Unless otherwise indicated, values present number of patients with percentage in parentheses.

### Table 2

Comparison of ICU hospitalization data of ICU patients with COVID-19 or with other viral pneumonia.

|                          | Other viral pneumonia, N = 45 | COVID-19, N = 99 | p-value |
|--------------------------|-------------------------------|------------------|---------|
| Acute respiratory failure at admission | 29 (64%) | 87 (88%) | <0.01 |
| Number of days in ICU    | 12 (7, 26)                    | 15 (6, 28)       | 0.76    |
| Bacterial pulmonary confection at admission | 15 (36%) | 6 (6.3%) | <0.01 |
| Cytolysis                | 23 (53%)                      | 57 (59%)         | 0.64    |
| Cholestasis              | 12 (28%)                      | 30 (31%)         | 0.84    |
| Death during ICU hospitalization performed | 15 (33%) | 47 (47%) | 0.16 |
| ICU hospitalization day which the CT was performed | 6 (1, 11) | 11 (2, 20) | 0.03 |
| Patient intubated        | 26 (58%)                      | 74 (75%)         | 0.06    |
| Patient with ECMO        | 1 (2.2%)                      | 16 (16%)         | 0.03    |

Values present number of patients with percentage in parentheses.

### Table 3

Comparison of abdominal imaging findings of ICU patients with COVID-19 or with other viral pneumonia.

|                          | Other viral pneumonia, N = 45 | COVID-19, N = 99 | p-value |
|--------------------------|-------------------------------|------------------|---------|
| Pre contrast             | 39 (87%)                      | 73 (74%)         | 0.13    |
| Arterial Phase           | 20 (44%)                      | 52 (53%)         | 0.47    |
| Portal venous phase      | 40 (83%)                      | 89 (90%)         | >0.99   |
| Lung involvement         |                               |                  | <0.01   |
| less than 5%             | 25 (56%)                      | 16 (16%)         |         |
| 5%−25% involvement       | 11 (24%)                      | 25 (25%)         |         |
| 26%−49% involvement      | 5 (11%)                       | 10 (10%)         |         |
| 50%−75% involvement      | 3 (6.7%)                      | 28 (28%)         |         |
| More than 75% involvement| 1 (2.2%)                      | 20 (20%)         |         |
| Abnormal abdominal findings | 27 (61%) | 63 (64%) | 0.94 |
| ‘Relevant abdominal findings’ | 18 (40%) | 42 (42%) | 0.93 |
| Intra-abdominal free fluid | 2 (4.4%) | 4 (4.0%) | >0.99 |
| Intra-abdominal free air | 22 (49%)                      | 35 (35%)         | 0.18    |
| Intra-abdominal fluid collection | 0 (0%) | 1 (1.0%) | >0.99 |
| Periportal edema         | 8 (18%)                       | 4 (4.0%)         | <0.01   |
| Gallbladder abnormality  | 10 (22%)                      | 21 (21%)         | >0.99   |
| Acute pancreatitis       | 3 (6.7%)                      | 14 (14%)         | 0.31    |
| Spleen infarcts          | 4 (8.9%)                      | 2 (2.0%)         | 0.08    |
| Adrenal hemorrhage       | 7 (16%)                       | 13 (13%)         | 0.90    |
| Renal infarcts           | 2 (4.4%)                      | 6 (6.1%)         | >0.99   |
| Bowel wall thickening    | 11 (24%)                      | 18 (18%)         | 0.52    |
| Small bowel involvement  | 6 (13%)                       | 5 (5.1%)         | 0.10    |
| Large bowel involvement  | 9 (20%)                       | 14 (14%)         | 0.52    |
| Bowel distension         | 4 (9.3%)                      | 13 (13%)         | 0.75    |
| Bowel ischemia           | 2 (4.4%)                      | 7 (7.1%)         | 0.72    |

Values present number of patients with percentage in parentheses.
same proportion of patients in both groups demonstrated gallbladder abnormalities (21/99 [21%] vs 10/45 [22%]; p = 0.99), adrenal hemorrhage (13/99 [13%] vs 7/45 [16%]; p = 0.90) and renal infarcts (6/99 [6.1%] vs 2/45 [4.4%]; p = 0.99). Acute pancreatitis signs were more commonly seen in COVID-19 patients but without reaching statistically significant difference between groups (14/99 [14%] vs 3/45 [6.7%] respectively; p = 0.31). On the 17 patients with acute pancreatitis, only 2 had biliary stones based on US evaluation, both in the COVID-19 patients. On the opposite, spleen infarcts were more commonly seen in patients with other viral pneumonia (2/99 [2.0%] vs 4/45 [8.9%]; p = 0.08). Regarding bowel wall abnormalities, bowel thickening was slightly more commonly seen in patients with other viral pneumonia (18/99 [18%] vs 11/45 [24%]; p = 0.52), however ischemia features were observed in higher rate in the COVID-19 group, although not yielding statistically significant differences (7/99 [7.1%] vs 2/45 [4.4%]; p = 0.75).

No significant predictive factor of relevant imaging findings was found whether regarding the type of viral pneumonia involvement (p = 0.76), the importance of lung involvement (p = 0.32), intubation (p = 0.39), ECMO (p = 0.07), date of CT request during ICU stay (0.14) and death (p = 0.11).

4. Discussion

The purpose of our study was to evaluate and compare the prevalence and type of abdominal involvements identified on CT scans in COVID-19 critically ill patients to those observed in critically ill patients with non-SARS-CoV-2 viral pneumonia.

The results of our study first confirm that abdominal findings are common in patients with viral pneumonia hospitalized in ICU. For patients with COVID-19, the rate of patients demonstrating abdominal abnormalities on CT scans remains in line with previous reports [4,16], apart from the lower rate of adrenal hemorrhage when compared to a previous study [8]. A significant number of studies indeed already reported abdominal symptoms related to SARS-CoV-2 and the utility of imaging and especially of CT [17] in detecting bowel ischemia in severe COVID 19 patients [18]. In addition, pancreatitis has also been associated to SARS-CoV-2 infections, which could be related to the presence of the ACE2 receptor on the pancreatic islet cells [17].

For other viral pneumonia such as Influenza, studies reporting abnormal imaging findings are scarce even if example of abdominal presentation of Influenza virus infection have been reported [19]. However uncertainty remains regarding the prevalence and significance of gastro-intestinal symptoms in patients with Influenza [20]. Moreover, some studies also reported cases of acute pancreatitis in the context of Influenza infection [21].

Interestingly, the prevalence and type of abdominal involvement in our study, as demonstrated on CT, was not significantly different in COVID-19 patients when compared to viral pneumonieae of other causes. In addition, the signs of bowel ischemia which could be related to thrombosis complications associated with SARS-CoV-2 [22], were more frequently seen within the COVID-19 group, but failed to reach a statistical difference with that observed in the non-COVID-19 patients. This also applies to pancreatic involvement, which has been reported after SARS-COV-2 infection [23,24], but which was also observed in non-COVID-19 patients.

The clinical data at admission, and the rate of patients with acute respiratory failure in both groups support a more critical illness in the COVID-19 group which is in line with a previous study comparing COVID-19 and Influenza [25].

Besides its retrospective design, this study suffers from limitations. The main limitation is the small number of patients analyzed. This is partly due to the limited number of patients with COVID-19 who underwent an abdominal and pelvic CT. However, a total of 727 patients were screened in our database to define the study population. Moreover, even if abnormal findings on CT are not uncommon, significant findings such as bowel ischemia were less frequently encountered. Second, because the study looked retrospectively at patient files over a study period extending from 2009 to 2021, the CT technique of the abdominal CT scan was not identical. Hence, arterial phase acquisitions were not systematically performed. However, the rate of unenhanced, arterial phase and portal phase acquisitions was similar in both groups. In addition, the combination of unenhanced and portal venous phase acquisitions is known to be highly specific when looking
for bowel ischemia [26]. Then, imaging analysis was done in consensus and not independently. Finally, as our study was monocentric and included patients throughout the different periods of the COVID-19 pandemic, the results might not be generalizable to other countries and cannot be associated to specific SARS-CoV-2 variants.

Further studies merging a larger number of patients are mandatory to determine whether this yields more systematic abdominal CT evaluation in patients with severe viral pneumonia.

5. Conclusion

The rate and severity of abdominal involvement demonstrated by CT in patients hospitalized in ICU for COVID-19 although high were not different to that observed in patients with other severe viral pneumonia.

Ethics approval and consent to participate

This retrospective study was approved by the local IRB and informed consent was waived.

Declaration of Competing Interest

None.

CRediT authorship contribution statement

Edouard Reizine: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing – original draft.

Sebastien Mule: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, Writing – original draft.

Nicolas De Prost: Formal analysis, Investigation, Methodology, Project administration, Resources, Validation, Writing – review & editing.

Nicolas Mongrand: Formal analysis, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing – review & editing.

Jean-François Deux: Validation, Visualization, Writing – review & editing.

Hicham Kobeiter: Validation, Visualization, Writing – review & editing.

Alain Luciani: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Writing – review & editing.

Financial support

None.

References

[1] Kato S, Ishiwata Y, Aoki R, et al. Imaging of COVID-19: an update of current evidences. Diagn Interv Imaging 2021;102(9):493–500. doi: 10.1016/j.diii.2021.05.006.
[2] Chassagnon G, Regard I, Soyer P, et al. COVID-19 after 18 months: where do we stand? Diagn Interv Imaging 2021;102(9):491–2. doi: 10.1016/j.diii.2021.06.003.
[3] Ma C, Cong Y, Zhang H. COVID-19 and the digestive system. Am J Gastroenterol 2020;115(7):1003–6. doi: 10.14309/ajg.0000000000000691.
[4] Goldberg-Stein S, Flask A, Parodi V, et al. Abdominopelvic CT findings in patients with novel Coronavirus disease 2019 (COVID-19). Abdom Radiol 2020;45 (9):2613–23 (NY). doi: 10.1007/s00261-020-02669-2.
[5] Bhayana R, Som A, Li MD, et al. Abdominal imaging findings in COVID-19: preliminary observations. Radiology 2020;201908. doi: 10.1148/radiol.2020201908.
[6] Dane B, Smereka P, Wain R, et al. Hypercoagulability in COVID-19: identification of arterial and venous thromboembolism in the abdomen, pelvis, and lower extremities. Am J Roentgenol 2020 American Roentgen Ray Society. doi: 10.2214/ AJR.20.23617.
[7] Ojha V, Mani A, Mukherjee A, et al. Mesenteric ischemia in patients with COVID-19: an updated systematic review of abdominal CT findings in 75 patients. Abdom Radil (NY) 2021; doi:10.1007/s00261-021-03337-9.
[8] Leyendecker P, Ritter S, Riuo M, et al. Acute adrenal infarction as an incidental CT finding and a potential prognostic factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol 2020. doi: 10.1007/s00330-020-06247-6.
[9] Vadvala HV, Shan A, Fishman EK, et al. CT angiography of abdomen and pelvis in critically ill COVID-19 patients: imaging findings and correlation with the CT chest score. Abdom Radiol 2021;46(7):3490–500 (NY). doi: 10.1007/s00261-021-03164-y.
[10] Pandanaboyana S, Moir J, Leedes JS, et al. SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut 2021;70(6):1061–9. doi: 10.1136/gutjnl-2020-323364.
[11] Koikman JJ, Mensink PFB. Non-occlusive mesenteric ischaemia: a common disorder in gastroenterology and intensive care. Best Pract Res Clin Gastroenterol 2003;17(3):457–73. doi: 10.1016/s1521-6918(03)00021-0.
[12] Vernadakis S, Heuer M, Brackmann C, et al. Intestinal ischemia secondary to H1N1 influenza. Am Surg 2012;78(1):144–6.
[13] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020 NEJMoa2015432. doi: 10.1056/NEJMoa2015432.
[14] Copin P, Zins M, Nuzzo A, et al. Acute mesenteric ischemia: a critical role for the radiologist. Diagn Interv Imaging 2018;59(3):123–34. doi: 10.1016/j.diii.2018.01.004.
[15] Lei Q, Li G, Ma X, et al. Correlation between CT findings and outcomes in 46 patients with Coronavirus disease 2019. Sci Rep 2021;11(11):1103. doi: 10.1038/s41598-020-79183-4.
[16] Lui K, Wilson MP, Low G. Abdominal imaging findings in patients with SARS-CoV-2 infection: a scoping review. Abdom Radiol 2020. doi: 10.1007/s00261-020-02739-5.
[17] Boraschi P, Giugliano L, Mercogliano G, et al. Abdominal and gastrointestinal manifestations in COVID-19 patients: is imaging useful? World J Gastroenterol 2021;27(28):4143–59. doi: 10.3748/wjg.v27.i26.4143.
[18] Parry AH, Wani AH, Yaseen M. Acute mesenteric ischemia in severe Coronavirus-19 (COVID-19): possible mechanisms and diagnostic pathway. Acad Radiol 2020;27(8):1190. doi: 10.1016/j.acra.2020.05.016.
[19] Vivar KL, Ueki TM. Influenza virus infection mimicking an acute abdomen in a female adolescent. Influenza Other Respir Viruses 2014;8(2):140–1. doi: 10.1111/irv.12222.
[20] Minodier L, Charrel RN, Ceccaldi P-E, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza virus in faecal samples: what do we know? Virol J 2015;12 (1):215. doi: 10.1186/s12985-015-0448-4.
[21] Aivalos C, Estfan E, Sewell S, et al. Acute pancreatitis caused by complications of influenza A in the setting of chronic lymphocytic leukemia. Cureus. 12(2): e7067. doi: 10.7755/cureus.7067.
[22] Buonvino S, Melino S. New consensus pattern in spike CoV-2: potential implications in coagulation process and cell-cell fusion. Cell Death Discov 2020;6:134. doi: 10.3348/1420-0200-00372-1.
[23] Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with Coronavirus disease 19 pneumonia. Gastroenterology 2020. doi: 10.1053/j.gastro.2020.01.055.
[24] Funt SA, Cohen SL, Wang JJ, et al. Abdominal pelvic CT findings compared between COVID-19 positive and COVID-19 negative patients in the emergency department setting. Abdom Radiol 2020;1:8 (NY). doi: 10.1007/s00261-020-02796-w.
[25] Pirohlo L, Cottenet J, Marlet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 2020;0(0) Elsevier. doi: 10.1016/s2213-2600(20)30527-0.
[26] Chuong AM, Corio L, Beassier H, et al. Assessment of bowel wall enhancement for the diagnosis of intestinal ischemia in patients with small bowel obstruction: value of adding unenhanced CT to contrast-enhanced CT. Radiology 2016;280 (1):98–107. doi: 10.1148/radiol.2016151020.